Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
$6.53
+0.3%
$6.37
$3.56
$12.92
$367.39M0.48266,293 shs236,545 shs
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
$1.09
-2.7%
$1.30
$0.77
$2.63
$93.76M1.051.40 million shs940,932 shs
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
$8.05
$8.03
$1.31
$8.10
$383.91M3.331.09 million shsN/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$8.54
-0.1%
$5.96
$3.55
$16.11
$388.50M0.572.08 million shs1.88 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
-2.40%+3.17%-1.81%+31.52%-46.38%
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
-2.61%-3.45%-26.80%-10.40%-41.97%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
0.00%0.00%-0.12%+2.16%+132.66%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
+0.12%+0.35%+75.20%+80.00%-43.64%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
2.679 of 5 stars
3.63.00.00.03.31.70.0
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
2.3563 of 5 stars
3.72.00.00.03.40.00.6
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
1.7788 of 5 stars
3.03.00.00.00.02.50.6
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
2.686 of 5 stars
2.94.00.00.02.32.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
3.14
Buy$29.00344.10% Upside
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
3.33
Buy$8.00633.94% Upside
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
2.00
Hold$10.8034.16% Upside
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
1.80
Reduce$9.6212.67% Upside

Current Analyst Ratings Breakdown

Latest CRDL, YMAB, VIGL, and ATXS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
8/13/2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$25.00 ➝ $26.00
8/13/2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
8/6/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$11.00 ➝ $8.60
8/5/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$8.60
8/5/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$26.00 ➝ $8.60
8/5/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
8/5/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$8.60
8/5/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetUnderperform ➝ Neutral$8.60
8/5/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$8.60
8/5/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
N/AN/AN/AN/A$2.93 per shareN/A
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
N/AN/AN/AN/A$0.10 per shareN/A
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/AN/AN/AN/A$1.75 per shareN/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$87.68M4.43N/AN/A$1.93 per share4.42
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
-$94.26M-$2.01N/AN/AN/AN/A-56.39%-36.08%11/12/2025 (Estimated)
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
-$26.77M-$0.34N/AN/AN/AN/A-232.26%-158.19%11/13/2025 (Estimated)
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
-$84.26M-$2.05N/AN/AN/AN/A-111.70%-74.67%11/6/2025 (Estimated)
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$29.67M-$0.50N/AN/AN/A-26.03%-24.60%-18.89%11/14/2025 (Estimated)

Latest CRDL, YMAB, VIGL, and ATXS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
-$0.11-$0.07+$0.04-$0.07N/AN/A
8/12/2025Q2 2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
-$0.61-$0.57+$0.04-$0.57$16.00 millionN/A
8/8/2025Q2 2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$0.27-$0.07+$0.20-$0.07$18.40 million$19.52 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
N/AN/AN/AN/AN/A
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
N/AN/AN/AN/AN/A
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/AN/AN/AN/AN/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
N/A
14.89
14.89
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
0.01
2.46
2.46
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/A
2.97
2.97
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/A
4.00
3.58

Institutional Ownership

CompanyInstitutional Ownership
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
98.98%
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
12.49%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
83.64%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
70.85%

Insider Ownership

CompanyInsider Ownership
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
4.50%
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
5.25%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
18.01%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
19.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
3056.44 million53.90 millionOptionable
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
2083.71 million79.32 millionNot Optionable
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
4047.69 million39.10 millionNot Optionable
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
15045.44 million36.49 millionOptionable

Recent News About These Companies

Brokerages Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) PT at $9.62
Y-mAbs (YMAB) Q2 Revenue Falls 14%

New MarketBeat Followers Over Time

Media Sentiment Over Time

Astria Therapeutics stock logo

Astria Therapeutics NASDAQ:ATXS

$6.53 +0.02 (+0.31%)
Closing price 04:00 PM Eastern
Extended Trading
$6.65 +0.12 (+1.84%)
As of 05:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Cardiol Therapeutics stock logo

Cardiol Therapeutics NASDAQ:CRDL

$1.09 -0.03 (-2.68%)
Closing price 04:00 PM Eastern
Extended Trading
$1.11 +0.02 (+1.83%)
As of 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Vigil Neuroscience stock logo

Vigil Neuroscience NASDAQ:VIGL

$8.05 0.00 (0.00%)
As of 08/5/2025

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

Y-mAbs Therapeutics stock logo

Y-mAbs Therapeutics NASDAQ:YMAB

$8.54 -0.01 (-0.12%)
Closing price 04:00 PM Eastern
Extended Trading
$8.54 0.00 (0.00%)
As of 04:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.